Kilambi News
Tuesday, November 17, 2026

Johnson & Johnson buys Ollin Biosciences for up to $3.3 billion

Life Sciences Tuesday, November 17, 2026 - Updated Nov 17, 2026 07:18

Johnson & Johnson will acquire eye drug developer Ollin Biosciences for $2.2 billion upfront plus $1.1 billion in milestones, a deal worth up to $3.3 billion.

Why it matters: The deal plants Johnson & Johnson in prescription eye medicines against Roche's blockbuster Vabysmo, with Blackstone putting up $750 million to fund the pivotal trials.

Data as of Deal announced Monday, November 16, 2026; terms from the companies' announcement as reported in full by Endpoints News and BioPharma Dive.

Johnson & Johnson said on Monday it will acquire Ollin Biosciences, a biotechnology startup developing medicines for eye diseases, for $2.2 billion upfront and a further $1.1 billion in milestone payments, valuing the deal at up to $3.3 billion. Ollin launched only last year, backed by Arch Venture Partners and TCGX among others, with a pair of medicines licensed from drug developers in China.

The prize asset is OLN324, a therapy originated by Shanghai-based Innovent Biologics. Like Roche’s Vabysmo, it targets two proteins, VEGF and Ang2, that drive wet age-related macular degeneration and diabetic macular edema. Ollin says the drug may be more potent and longer lasting than existing treatments, and Phase 1b data supported that potential. Four Phase 3 studies are running, two in wet AMD and two in diabetic macular edema, testing OLN324 against Lucentis or Eylea.

Blackstone Life Sciences is putting up $750 million to support the Phase 3 program, in return for eligibility for milestone payments and royalties if the drug reaches the market. “OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, Johnson & Johnson’s ophthalmology disease area leader, in a statement.

The acquisition is a strategic step for a Johnson & Johnson eye business built mainly on contact lenses, devices and surgical equipment, with only limited exposure to prescription eye medicines. RBC Capital Markets analyst Trung Huynh called the fit logical but said the price appears high and questioned how differentiated OLN324 will prove in a crowded market. Ollin’s second therapy, OLN102, is a preclinical potential competitor to the thyroid eye disease drug Tepezza.

Sources

  1. J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B - Endpoints News - 2026-11-16
  2. J&J bets $2.2B on Ollin's vision loss drug - BioPharma Dive - 2026-11-16